Structured evidence table for Proanthocyanidins Skin Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Proanthocyanidins Skin Randomized Trial | Emerging evidence indicates that the overactivation of T-helper 17 (Th17) cells and the release of their pro-inflammatory cytokines, mainly interleukin-17A (IL-17A) and interleukin-17F (IL-17F), propel the inflammatory cascade central to IMIDs (). | 3 | Yang Yu (2026) | Proanthocyanidins in immune-mediated inflammatory diseases: molecular mechanisms and therapeutic potential |
| Proanthocyanidins Skin Randomized Trial | Moreover, immune imbalance resulting from reduced numbers or functional impairment of regulatory T (Treg) cells contributes significantly to the development of these diseases (). | 3 | Yang Yu (2026) | Proanthocyanidins in immune-mediated inflammatory diseases: molecular mechanisms and therapeutic potential |
| Proanthocyanidins Skin Randomized Trial | They offer a great advantage of simultaneously targeting multiple inflammatory pathways, with early and continuous use markedly lowering disability risk (;). | 3 | Yang Yu (2026) | Proanthocyanidins in immune-mediated inflammatory diseases: molecular mechanisms and therapeutic potential |
| Proanthocyanidins Skin Randomized Trial | These disorders share key characteristics in their clinical manifestation, target organs, and long-term outcomes. | 3 | Yang Yu (2026) | Proanthocyanidins in immune-mediated inflammatory diseases: molecular mechanisms and therapeutic potential |
| Proanthocyanidins Skin Randomized Trial | This review summarizes and critically evaluates current evidence on the geroprotective potential of Crataegus species, integrating data from phytochemical, pharmacological, and mechanistic studies. | 4 | Kydyrbayeva A (2026) | <i>Crataegus</i> Species as a Source of Geroprotective Phytochemicals: Biological Activities, Molecular Mechanisms and Therapeutic Perspectives. |
| Proanthocyanidins Skin Randomized Trial | We discuss the growing evidence that these phytochemicals target multiple hallmarks of aging by modulating oxidative stress, chronic low-grade inflammation (inflammaging), mitochondrial dysfunction, cellular senescence, and the senescence-associated secretory phenotype (SASP). | 4 | Kydyrbayeva A (2026) | <i>Crataegus</i> Species as a Source of Geroprotective Phytochemicals: Biological Activities, Molecular Mechanisms and Therapeutic Perspectives. |
| Proanthocyanidins Skin Randomized Trial | Although preclinical evidence strongly supports the multi-target geroprotective properties of Crataegus species, clinical validation remains limited. | 4 | Kydyrbayeva A (2026) | <i>Crataegus</i> Species as a Source of Geroprotective Phytochemicals: Biological Activities, Molecular Mechanisms and Therapeutic Perspectives. |
| Proanthocyanidins Skin Randomized Trial | Population aging has intensified the search for natural compounds capable of promoting healthy aging and preventing age-related diseases. | 4 | Kydyrbayeva A (2026) | <i>Crataegus</i> Species as a Source of Geroprotective Phytochemicals: Biological Activities, Molecular Mechanisms and Therapeutic Perspectives. |
Source documents